SCHEMBL708444

SCHEMBL708444

Clc1ccc(N2CCCCC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
HTT P42858 2/20 0.63
LMNA P02545 2/20 0.63
HPGD P15428 1/20 0.63
AKR1C3 P42330 1/20 0.63
HTR3E A5X5Y0 1/20 0.61
HTR3B O95264 1/20 0.61
ADRB1 P08588 1/20 0.61
HTR3A P46098 1/20 0.61
HTR3D Q70Z44 1/20 0.61
HTR3C Q8WXA8 1/20 0.61
SIGMAR1 Q99720 1/20 0.61
MAPT P10636 4/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
KDM4E B2RXH2 3/20 0.58
POLB P06746 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
NPC1 O15118 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL708442 1.00 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2HTTLMNAHPGD
Hydrochloric Acid SCHEMBL2159161 0.98 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL1822749 0.97 HTR3E (0.64) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL24103508 0.92 SIGMAR1 (0.64) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL870704 0.87 HTR3E (0.70) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL29998630 0.87 HTR3E (0.70) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL6887590 0.87 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL11644110 0.86 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL10772793 0.85 MAPT (0.60) ALDH1A1SMN1; SMN2HTTLMNAHPGD
SCHEMBL2174173 0.84 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2HTTLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 US disclosed
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
CN-112341376-B Preparation method of cycloolefine amine sulfone derivative 温州医科大学 2022-12-06 CN disclosed
WO-2022226668-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed
CN-115087440-A TRPML modulators 卡斯玛治疗公司 2022-09-20 CN disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
CN-110143914-B Preparation method of apixaban intermediate 常州恒邦药业有限公司 2022-03-29 CN disclosed
EP-3459948-B1 FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2021-11-17 EP disclosed
WO-2001009138-A2 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2001-02-08 WO disclosed
US-6140344-A FOR TREATING PATHOLOGICAL CONDITIONS SUCH AS ASTHMA, RHINITIS, ECZEMA AND PARASITIC INFECTIONS FEATURING TISSUE EOSINOPHILIA SYNTEX (U.S.A.) INC. (US) 2000-10-31 US disclosed
CN-1256333-A Resin composition for coating paper and coating composition for paper and coated paper thereof SUMITOMO CHEMICAL CO (JP) 2000-06-14 CN disclosed
WO-2000031033-A1 PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2000-06-02 WO disclosed
WO-2000029377-A1 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III F. HOFFMANN-LA ROCHE AG (CH) 2000-05-25 WO disclosed
EP-0903349-A2 CCR-3 receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 1999-03-24 EP disclosed
EP-0434341-B1 Diazine derivatives ZENECA LTD (GB) 1995-05-17 EP disclosed
EP-0600952-A1 AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. MERCK SHARP & DOHME (GB) 1994-06-15 EP disclosed
WO-1993004040-A1 AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MERCK SHARP & DOHME LIMITED (GB) 1993-03-04 WO disclosed
US-4577025-A Method of preparing α-aromatic propionic acids and intermediates thereof NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1986-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT ALDH1A1 481/4885SMN1; SMN2 2118/4885HTT 1725/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT ALDH1A1 552/4885SMN1; SMN2 2010/4885HTT 1493/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT ALDH1A1 481/4885SMN1; SMN2 2118/4885HTT 1725/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT ALDH1A1 481/4885SMN1; SMN2 2118/4885HTT 1725/4885
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 ALDH1A1 1521/4885SMN1; SMN2 3873/4885HTT 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.